NASDAQ:BIAF bioAffinity Technologies (BIAF) Stock Price, News & Analysis $4.74 -0.90 (-16.01%) As of 03:11 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC Filings About bioAffinity Technologies Stock (NASDAQ:BIAF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BIAF alerts:Sign Up Key Stats Today's Range$4.75▼$5.4850-Day Range$4.56▼$15.2752-Week Range$4.56▼$80.70Volume555,489 shsAverage Volume1.41 million shsMarket Capitalization$2.85 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview bioAffinity Technologies, Inc. is a biotechnology company focused on developing diagnostic and therapeutic products for cancer and other diseases. The company’s technology platform uses porphyrin-based compounds designed to selectively interact with cancer cells, supporting applications in disease detection and treatment. Its lead diagnostic product, CyPath Lung, is a noninvasive urine-based test being developed to aid in the detection of lung cancer. The test is designed to use a porphyrin-based agent that interacts with abnormal cells in the lungs and can subsequently be detected in a urine sample. CyPath Lung has received Breakthrough Device designation from the U.S. Food and Drug Administration, although regulatory status and availability may vary by jurisdiction. bioAffinity Technologies is headquartered in Albuquerque, New Mexico, and serves the medical and biotechnology markets through the development of products intended to improve the early identification and treatment of cancer. The company is led by Maria Zannes, who serves as president and chief executive officer.AI Generated. May Contain Errors. Read More bioAffinity Technologies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks6th Percentile Overall ScoreBIAF MarketRank™: bioAffinity Technologies scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingbioAffinity Technologies has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoveragebioAffinity Technologies has only been the subject of 1 research reports in the past 90 days.Read more about bioAffinity Technologies' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of bioAffinity Technologies is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of bioAffinity Technologies is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatiobioAffinity Technologies has a P/B Ratio of 0.20. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about bioAffinity Technologies' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.17% of the float of bioAffinity Technologies has been sold short.Short Interest Ratio / Days to CoverbioAffinity Technologies has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in bioAffinity Technologies has recently increased by 61.89%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldbioAffinity Technologies does not currently pay a dividend.Dividend GrowthbioAffinity Technologies does not have a long track record of dividend growth. News and Social Media1.9 / 5News Sentiment0.07 News SentimentbioAffinity Technologies has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 12 news articles for bioAffinity Technologies this week, compared to 3 articles on an average week.Search InterestOnly 8 people have searched for BIAF on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, bioAffinity Technologies insiders have not sold or bought any company stock.Percentage Held by Insiders2.68% of the stock of bioAffinity Technologies is held by insiders.Percentage Held by Institutions1.64% of the stock of bioAffinity Technologies is held by institutions.Read more about bioAffinity Technologies' insider trading history. Receive BIAF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for bioAffinity Technologies and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BIAF Stock News HeadlinesWallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules2 hours ago | prnewswire.combioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules3 hours ago | businesswire.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.October 9 at 1:00 AM | Porter & Company (Ad)BioAffinity Prices $4 Mln Direct Offering, Adds Warrants To Support CyPath Lung Sales4 hours ago | rttnews.comUpdate: BioAffinity Technologies Prices $4 Million Registered Direct OfferingOctober 8 at 6:07 PM | finance.yahoo.comBioAffinity Technologies receives Japanese patent allowance for CyPath Lung AI diagnostic testOctober 8 at 6:07 PM | msn.comWallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq RulesOctober 8 at 1:30 PM | prnewswire.combioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built AlgorithmOctober 8 at 1:05 PM | finance.yahoo.comSee More Headlines BIAF Stock Analysis - Frequently Asked Questions How have BIAF shares performed this year? bioAffinity Technologies' stock was trading at $17.70 at the beginning of 2026. Since then, BIAF stock has decreased by 72.5% and is now trading at $4.8640. How were bioAffinity Technologies' earnings last quarter? bioAffinity Technologies, Inc. (NASDAQ:BIAF) announced its quarterly earnings data on Friday, August, 7th. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($31.50) by $30.86. The firm had revenue of $1.51 million for the quarter, compared to analysts' expectations of $1.70 million. bioAffinity Technologies had a negative net margin of 257.30% and a negative trailing twelve-month return on equity of 220.52%. When did bioAffinity Technologies' stock split? bioAffinity Technologies's stock reverse split before market open on Friday, September 19th 2025.The 1-30 reverse split was announced on Wednesday, September 17th 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 18th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did bioAffinity Technologies IPO? bioAffinity Technologies (BIAF) raised $8 million in an IPO on Thursday, September 1st 2022. The company issued 1,300,000 shares at a price of $6.00-$6.25 per share. WallachBeth Capital served as the underwriter for the IPO and Craft Capital Management was co-manager. How do I buy shares of bioAffinity Technologies? Shares of BIAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of bioAffinity Technologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that bioAffinity Technologies investors own include Lowe's Companies (LOW), Meta Platforms (META), Costco Wholesale (COST), Intel (INTC), Alnylam Pharmaceuticals (ALNY) and Company Calendar Last Earnings8/07/2026Today10/09/2026Next Earnings (Estimated)11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (5m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 BIAF's financial health is in the Yellow zone, according to TradeSmith. BIAF has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Providers & Services Sub-IndustryHealthcare Services Current SymbolNASDAQ:BIAF CIK1712762 Webwww.bioaffinitytech.com Phone210-698-5334FaxN/AEmployees57Year Founded2014Profitability EPS (Trailing Twelve Months)($109.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.91 million Net Margins-257.30% Pretax Margin-257.18% Return on Equity-220.52% Return on Assets-136.76% Debt Debt-to-Equity Ratio0.14 Current Ratio1.44 Quick Ratio1.41 Sales & Book Value Annual Sales$5.85 million Price / Sales0.49 Cash FlowN/A Price / Cash FlowN/A Book Value$24.25 per share Price / Book0.20Miscellaneous Outstanding Shares601,000Free Float585,000Market Cap$2.89 million OptionableNot Optionable Beta-1.25 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:BIAF) was last updated on 10/9/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bioAffinity Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share bioAffinity Technologies With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BIAF Stock Alerts